Live Last read · last published · next check
Twelve research teams from the LDI were awarded $12,903,057 in combined funding through the Canadian Institutes of Health Research (CIHR) Fall 2025 Project Grant and Team Grants: Bringing Biology to Cancer Prevention competitions.
The research provides new insights into the prognostic value of ctDNA and its ability to guide personalized treatment strategies for patients with triple-negative breast cancer.
The study shows that glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which include Ozempic®, Rybelsus® and other widely- prescribed drugs for type 2 diabetes and obesity management, may increase the risk of developing gastroesophageal reflux disease (GERD) and its complications compared to sodium–glucose cotransporter-2 (SGLT-2) inhibitors (such as Brenzavvy™, Invokana®, etc.).
Innovative strategy has the potential to revolutionize the treatment of breast cancer, particularly for patients who have developed resistance to targeted therapies.
Nine researchers, one postdoctoral fellow, 17 PhD students and three master’s students from the Lady Davis Institute for Medical Research (LDI) are the recipients of FRQ salary and research awards within the framework of the 2025-2026 competitions.
Despite previous concerns, findings provide reassurance about the psychiatric safety of these drugs, say researchers.
New research sheds light on potential therapeutic targets for cardiovascular disease prevention.
Two new studies examine how vaping during adolescence affects the lungs and heart.
Michael Hier, Associate Researcher at the LDI, has received the Harvey H. Sigman Undergraduate Teaching Excellence Award from the Department of Surgery at McGill University.
Machelle Wilchesky, Principal Investigator at the LDI and Director of the Donald Berman Maimonides Centre for Research in Aging, was appointed Scientific Director of the McGill Primary Care Practice-based Research Network (PBRN) on July 1, 2024.
